ArticleBehavioural brain research2019
5-Fluorouracil impairs attention and dopamine release in rats.
Article in Behavioural brain research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Cognitive impairments associated with chemotherapy in women with breast cancer: a meta-analysis and meta-regression.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Pooled it
- Cancer therapy-related cognitive impairment, part 1: an integrative clinical-mechanistic framework from phenotypes to convergent neurobiological pathways.Pharmacological reports : PR · 2026Review
- Chemotherapy-Induced Brain Damage: Mechanisms and Insights from Rodent Models.Brain sciences · 2026Review
- A systematic review of the neurobiological mechanisms of chemotherapy-induced deficits in executive functions.Brain, behavior, & immunity - health · 2026Review
- Cancer therapy and cachexia.The Journal of clinical investigation · 2025Review
- Mechanism of cytarabine-induced neurotoxicity.Nature · 2025Article
- Doxorubicin treatment has a biphasic effect over time on dopamine release and impulsive behavior in Wistar rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Natural products for the treatment of chemotherapy-related cognitive impairment and prospects of nose-to-brain drug delivery.Frontiers in pharmacology · 2024Review
- Cancer related cognitive impairment: a downside of cancer treatment.Frontiers in oncology · 2024Review
- An update on neurobiological mechanisms involved in the development of chemotherapy-induced cognitive impairment (CICI).Toxicology reports · 2023Review
- Dopamine Release Impairments Accompany Locomotor and Cognitive Deficiencies in Rotenone-Treated Parkinson's Disease Model Zebrafish.Chemical research in toxicology · 2022Article
- Mechanisms of Chemotherapy-Induced Neurotoxicity.Frontiers in pharmacology · 2022Review
- Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.Archives of toxicology · 2022Review
- Animal models of chemotherapy-induced cognitive decline in preclinical drug development.Psychopharmacology · 2021Review
- Microglia in Cancer Therapy-Related Cognitive Impairment.Trends in neurosciences · 2021Review
- Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases.EMBO molecular medicine · 2020Review
- Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment.Current opinion in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Chemotherapy related cognitive impairment (CTRC; "chemobrain") is a syndrome that is associated with the impairment of various aspects of cognition, including executive function, processing speed, and multitasking. The role of neurotransmitter release in the expression of cognitive impairments is not well known. In this work we employed a newly developed behavioral paradigm to measure attentional shifting, a fundamental component of executive function, in rats treated with 5-fluorouracil (5-FU), a commonly used cancer chemotherapy agent. We found that one and two weeks of 5-FU treatment significantly impaired attentional shifting compared to baseline, while saline treatment had no effect. Post-mortem analysis of these rats revealed that 5-FU caused a significant overall decrease in dopamine release as well. Collectively, these results demonstrate the feasibility of our attentional shifting paradigm for evaluating the cognitive effects of chemotherapy treatment. Moreover, these results support the need for additional studies to determine if impaired dopamine release plays a role in chemobrain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.